Brokerages Expect Recro Pharma, Inc. (NASDAQ:REPH) to Post -$0.53 Earnings Per Share
Wall Street analysts expect that Recro Pharma, Inc. (NASDAQ:REPH) will report ($0.53) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Recro Pharma’s earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.59). Recro Pharma reported earnings of ($0.83) per share in the same quarter last year, which would indicate a positive year over year growth rate of 36.1%. The firm is scheduled to issue its next earnings results on Thursday, August 10th.
On average, analysts expect that Recro Pharma will report full-year earnings of ($2.35) per share for the current fiscal year, with EPS estimates ranging from ($2.51) to ($2.24). For the next fiscal year, analysts expect that the business will report earnings of ($2.60) per share, with EPS estimates ranging from ($3.25) to ($2.08). Zacks’ EPS averages are an average based on a survey of analysts that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.15. The company had revenue of $18.74 million for the quarter, compared to analyst estimates of $15.58 million. Recro Pharma had a negative net margin of 45.15% and a negative return on equity of 61.09%.
REPH has been the topic of several research reports. Janney Montgomery Scott lowered shares of Recro Pharma from a “buy” rating to a “fair value” rating and dropped their price objective for the company from $21.00 to $6.50 in a research note on Wednesday, June 14th. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research note on Wednesday, May 17th. Piper Jaffray Companies set a $11.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research note on Tuesday, July 25th. Finally, Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $14.00.
In other Recro Pharma news, major shareholder James E. Flynn sold 32,447 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $6.59, for a total value of $213,825.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James E. Flynn sold 110,447 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $6.39, for a total transaction of $705,756.33. The disclosure for this sale can be found here. Insiders sold 970,391 shares of company stock valued at $7,076,242 over the last three months. Insiders own 21.60% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Marshall Wace North America L.P. acquired a new stake in Recro Pharma during the first quarter valued at approximately $1,601,000. MARSHALL WACE ASIA Ltd acquired a new stake in Recro Pharma during the first quarter valued at approximately $1,601,000. Cadence Capital Management LLC increased its stake in Recro Pharma by 32.4% in the second quarter. Cadence Capital Management LLC now owns 124,491 shares of the specialty pharmaceutical company’s stock valued at $875,000 after buying an additional 30,455 shares in the last quarter. TFS Capital LLC acquired a new stake in Recro Pharma during the first quarter valued at approximately $827,000. Finally, Renaissance Technologies LLC increased its stake in Recro Pharma by 245.1% in the first quarter. Renaissance Technologies LLC now owns 63,500 shares of the specialty pharmaceutical company’s stock valued at $555,000 after buying an additional 45,100 shares in the last quarter. 64.15% of the stock is owned by institutional investors.
Shares of Recro Pharma (REPH) traded down 2.53% during trading on Friday, hitting $7.32. 86,543 shares of the company’s stock were exchanged. Recro Pharma has a 1-year low of $5.81 and a 1-year high of $10.85. The stock’s 50 day moving average is $7.16 and its 200 day moving average is $7.64. The firm’s market capitalization is $139.45 million.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.